Clinical Trial Update: Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating lenvatinib for metastatic neuroendocrine tumors has completed. Results were posted on July 24, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2025-07-24